AbstractNew oral anticoagulants are important pharmaceuticals for prevention of stroke and systemic embolism in non-valvular atrial fibrillation patients. Recently for prevention and treatment of thromboembolism in atrial fibrillation patients antagonists vitamin K, in particular warfarin were used. However, narrow therapeutic window, the need for lifelong monitoring of coagulation and negative interactions with many food products and pharmaceuticals reduces its use. Besides, long-term use of warfarin and its antagonism against vitamin K, which is the regulator of elimination of calcium from the body, can cause calcification of the coronary arteries and valvular heart. In connection with this new oral anticoagulants: dabigatran, rivaroxaban, apixaban are actively used in modern conditions. Their efficacy and safety is proved in randomized clinical trials: RF-LY, ROCKET -AF, ARISTOTLE.
Camm A.J., Kirchhof P., Lip G.Y. et al. ESC Committee for Practice Guidelines. Guidelines for the management of atrial fibrillation: the Task Force for the Management of Atrial Fibrillation of the European Society of Cardiology (ESC). 2010; 12: 1360-1420.
Ruff C.T., Giugliano R.P., Antman E.M. et al. Evaluation of the novel factor Xa inhibitor edoxaban compared with watfarin in patients with atrial fibrillation:design and rationale for the Effective Anticoagulation with Factor Xa Next Generation in Atrial fibrillation - Thrombolysis in Myocardial Infarction Study 48 (ENGAGE AF-TIMI 48). American Heart Journal. 2010; 160: 635-641.
Аnsell J., Hirsh J., Hylek E. et al. Pharmacology and management of the vitamin K antagonists: American College of Chest Evidence-Based Clinical Practice Guidelines. Chest. 2008; 133: 160-198.
Baker W.L., Cios D.A., Sander S.D. et al. Meta-analysis to assess the quality of warfarin control in atrial fibrillation patients in United States. Journal of Managed Care Pharmacy. 2009; 15: 244-52.
Baker W. L, Phung O.J. et al. Showing results for systematic review and adjusted indirect comparison meta-analysis of oral anticoagulants inatrial fibrillation - 2012. Circulation Cardiovascular Quality and Outcomes. 2012; 5(5): 711-9.
Connolly S.J., Ezekowitz M.D., Yusuf S. et al. Newly identified events in the RE-LY trial. New England Journal of Medicine. 2010; 363: 1875-1876.
Hohnloser S.H., Oldgren J., Yang S. et al. Myocardial ischemic events in patients with atrial fibrillation treated with dabigatran or warfarin in the RE-LY (Randomized Evaluation of Long-Term Anticoagulation Therapy) trial. Circulation. 2012; 125: 669-676.
Connolly S.J., Ezekowitz M.D., Yusuf S. et al. Dabigatran versus warfarin in patients with atrial fibrillation. New England Journal of Medicine. 2009; 361: 139-1151.
Patel M.R., Mahaffey K.W., Garg J. et al. ROCKET AF Investigators. Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. New England Journal of Medicine. 2011; 365: 883-891.
Connolly S.J., Eikelboom J., Joyner C. et al. AVERROES Steering Committee and Investigators. Apixaban in patients with atrial fibrillation. New England Journal of Medicine. 2011; 364: 806-817.
Ahrens I., Lip G.Y., Peter K. et al. New oral anticoagulant drugs in cardiovascular disease. Journal of Thrombosis and Haemostasis. 2010; 104: 49-60.
Oldgren J., Alings M., Darius H., Diener H.C. RE-LY Investigators. Risks for stroke, bleeding, and death in patients with atrial fibrillation receiving dabigatran or warfarin in relation to the CHADS2score: a subgroupanalysis of the RE-LY trial. Annals of Internal Medicine. 2011; 155: 660-667.
Pradaxa (dabigatran etexilate), prescribing information. Boehringer Ingelheim Pharmaceutical Inc., Ridgefield, CT, USA 2010.
Schaefer H.J., Leung W., Wu L. Translational insights into traumatic brain injury occurring during dabigatran or warfarin anticoagulation. Journal of Cerebral Blood Flow & Metabolism. 2014.
Ice D. S., Shapiro T.A., Eric M. Unanswered Questions in Patients With Concurrent Atrial Fibrillation and Acute Coronary Syndrome. The American Journal of Cardiology. 113: 888-896.
Lip G.Y, Lane D.A. et al. Does warfarin for stroke thromboprophylaxis protect against MI in atrial fibrillation patients? American Journal of Medicine. 2010; 123: 785-789.
Uchino K., Hernandez A.V. et al. Dabigatran association with higher risk of acute coronary events: meta-analysis of noninferiority randomized controlled trials. Archives of Internal Medicine. 2012; 172: 397-402.
Go A.S., Hylek E.M., Chang Y. et al. Anticoagulation therapy for stroke prevention in atrial fibrillation: how well do randomized trial translate into clinical practice? Journal of the American Medical Association. 2003; 290: 2658-92.
Nieuwlaat R., Capucci A., Camm A.J. et al. Atrial fibrillation management: a prospective survey in ESC member countries: the Euro Heart Survey on atrial fibrillation. European Heart Journal. 2005; 26: 2422-34.
Вirman-Deych E., Radford M.J. Use and effectIveness of warfarin in MedIcare beneficiaries with atrial fibrillation. Stroke. 2006; 37: 1070-4.
Eikelboom J.W., Weitz J.I. et al. New anticoagulants. Circulation. 2010; 121: 1523-32.
Granger C.B., Alexander J.H., McMurray J.J. et al. ARISTOTLE Committees and Investigators. Apixaban versus warfarin in patients with atrial fibrillation. New England Journal of Medicine. 2011; 365: 981-992.
Glader E.L., Sjolander M., Eriksson M. et al. Persistent use of secondary preventive drugs declines rapidly during the first 2 years after stroke. Stroke. 2010; 41: 397-401.
Fang M.C., Go A.S., Chang Y. et al. Warfarin discontinuation after starting warfarin for atrial fibrillation. Circulation Cardiovascular Quality and Outcomes. 2010; 3: 624-31.
Hart R.G., Pearce L.A., Aguilar M.I. et al. Meta-analysis:antithrombotic therapy to prevent stroke in patients who have nonvalvular atrial fibrillation. Annals of Internal Medicine. 2007; 146: 857-67.
The ACTIVE Investigators. Effect of clopidogrel addded to aspirin in patients with atrial fibrillation. New England Journal of Medicine. 2009; 360: 2066-78.
Hart R., Pearce L.A., Aguilar I.M. et al. Adjusted -dose warfarin versus aspirin for preventing stroke in patients atrial fibrillation. Annals of Internal Medicine. 2007; 147: 590-2.
Connolly S., Pogue J., Hart R. et al. Clopidogrel plus aspirin versus oral anticoagulation for atrial fibrillation in the Atrial fibrillation Clopidogrel Trial with Irbesartan for Vascular Event (ACTIVE W): a randomized controlled trial. Lancet. 2006; 367: 1903-12.
Lopes R.D., Alexander J.H., AL-Khatib S.M. et al. Apixaban for Reduction in Stroke and Other Thomboembolic Events in atrial fibrillation(ARISTOTLE) trial: desing and rationale. American Heart Journal. 2010; 159: 331-9.
Hart R.G., Tonarelli S.B., Pearce L.A. et al. Avoiding central nervous system bleeding during antithrombotic therapy: recent data and ideas. Sroke. 2005; 36: 1588-93.
Wyse D.G., Slee A., Epstein A.E. et al.Alternative endpoints for mortality in studies of patients with atrial fibrillation: the AFFIRM study experience. Heart Rhythm. 2004; 1: 531-7.
Lip G.Y., Larsen T.B., Skjoth F. et al. Indirect comparisons of new oral anticoagulant drugs for efficacy and safety when used for stroke prevention in atrial fibrillation. Journal of the American College of Cardiology. 2012; 60: 738-746.
Tripodi A. Measuring the anticoagulant effect of direct factor Xa inhibitors. Is the anti-Xa assay preferable to the prothrombin time test? Journal of Thrombosis and Haemostasis. 2011; 105: 735-736.
Barrett Y.C., Wang Z., Frost C. et al. Clinical laboratory measurement of direct factor Xa inhibitors: anti-Xa assay is preferable to prothrombin time assay. Journal of Thrombosis and Haemostasis. 2010; 104: 1263-1271.
Banerjee A., Lane D.A., Torp-Pedersen C. et al. Net clinical benefit of new oral anticoagulants (dabigatran, rivaroxaban, apixaban) versus no treatment in a ‘real world’ atrial fibrillation population: a modelling analysis based on a nationwide cohort study. Journal of Thrombosis and Haemostasis. 2012; 107: 584-589.
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.